Press Releases
Imaging Biometrics Enters Agreement with MedImageMetric to Commercialize QSM Technology
September 16, 2025 – Imaging Biometrics, LLC (IB), a leading provider of advanced MRI analytics, is pleased to announce an agreement with MedImageMetric, LLC (MIM) to commercialize its patented quantitative…
IQ-AI Appoints Renowned Brain Tumor Champion to Board of Directors
November 20, 2024 – IQ-AI Ltd is pleased to announce the appointment of Dr. Al Musella, MD, a prominent figure in the field of brain tumor research and treatment, to its…
Imaging Biometrics Expands Distribution
November 20, 2024 – Imaging Biometrics (IB) has renewed its distribution agreement with GE HealthCare. This agreement aims to expand the distribution of IB’s advanced imaging solutions. GE HealthCare will…
Expanded Access Program for gallium maltolate (GaM) Now Open – July 3, 2024
OAKLAND, CALIFORNIA, UNITED STATES, July 3, 2024 /EINPresswire.com/ — xCures, a healthcare data platform provider, announced that the US Food and Drug Administration (FDA) has approved an Expanded Access Program…
Imaging Biometrics Software Enhances Clinical Decision-Making at Insel Gruppe AG
May 17, 2024 — Imaging Biometrics (IB), Elm Grove, WI, a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), announces the successful deployment of its state-of-the-art software at Insel Gruppe…
Imaging Biometrics Touts DSC Study Results Using IB Rad Tech
May 10, 2024 – Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), is highlighting a study published in Neuroradiology that validates the benefit of IB Rad…
Imaging Biometrics’ DSC Perfusion-Derived FTB Maps Enhance Radiologist Confidence
March 12, 2024 — Imaging Biometrics, LLC (IB), Elm Grove, WI, a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI, OTCBB: IQAIF), is pleased to announce the results of a…
IB Neuro Reveals the Hidden Secrets of High-Grade Glioma’s Invasive Margins
October 18, 2023 — Imaging Biometrics, LLC (IB), Milwaukee, WI, a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), is pleased to announce the results of a landmark study published…
Reduced Gadolinium Approach Validated with IB Neuro on 1.5T MR Scanners
September 21, 2023 – Imaging Biometrics, LLC is pleased to announce the results of a study that validates IB Neuro’s processing of reduced-dose gadolinium-based contrast agent (GBCA) perfusion studies on…
New Studies Show Oral Gallium Maltolate (GaM) Inhibits Pediatric Tumor Growth
June 27, 2023 — Imaging Biometrics, LLC (IB), a wholly-owned subsidiary of IQ-AI Ltd (LSE: IQAI, OTCQB: IQAIF), is pleased to share the results of two pre-clinical studies that were…